EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Much like Pfizer, Merck (NYSE: MRK) has had a couple of unprofitable quarters on an operational basis recently, though it also has more than 30 programs in phase 3 clinical trials, at least some ...

MANILA, Philippines — The Commission on Audit (CoA) shared its experience in auditing Gender and Development (GaD) funds with delegates from the Royal Government of Cambodia. Conducted at CoA's ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...

Chief of Army Staff General Syed Asim Munir has expressed desire to further strengthen military partnership between Pakistan and Belarus. He was talking to Belarusian Prime Minister Roman Golovchenko ...

The Chief of Army Staff (COAS), Lt.-Gen. Taoreed Lagbaja has reaffirmed the commitment of the Nigerian Army to promoting gender inclusiveness and integration in all its activities and operations.

The Global Myocardial Infarction Therapeutics Market is estimated to be valued at USD 15.56 billion in 2023 and is projected to grow at a CAGR of 4.19% over the forecast period 2024-2032. Read the ...

The Nigerian Army has commended the Lawmaker representing Kogi West Senator Sunday Karimi for building and donating Forward Operating Base (FOB) in Egbe, Yagba East Local Government Area of the ...

Chief of Army Staff General Syed Asim Munir is on an official visit to Saudi Arabia and the UAE. During his week-long visit, the Army Chief will be meeting the senior leadership of both the brotherly ...

Type 2 diabetes is often viewed as a disorder of glucose metabolism. But many factors come into play in this condition, with obesity a prime risk factor and cardiovascular disease a major result.

However, the company opted to buy Nimbus Therapeutics' acetyl-CoA carboxylase (ACC) programme instead. Gilead will buy Nimbus Therapeutics' liver drug subsidiary Nimbus Apollo in a $1.2 billion deal.